Details for Patent: 9,067,896
✉ Email this page to a colleague
Which drugs does patent 9,067,896 protect, and when does it expire?
Patent 9,067,896 protects TRUSELTIQ and is included in one NDA.
This patent has forty-six patent family members in thirty-three countries.
Summary for Patent: 9,067,896
| Title: | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
| Abstract: | The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin- -1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, amorphous and anhydrous crystalline polymorphs of its monophosphoric acid salt, and the hydrochloride salt, including its dihydrate. The present technology further provides methods for preparing the various forms, compositions containing them, and methods of treatment employing them. |
| Inventor(s): | Berghausen; Joerg (Lorrach, DE), Kapa; Prasad K (Parsippany, NJ), McKenna; Joseph (Nazareth, PA), Slade; Joel (Flanders, NJ), Wu; Raeann (Pine Brook, NJ), Du; Zhengming (Parsippany, NJ), Stowasswer; Frank (Murg, DE) |
| Assignee: | Novartis AG (Basel, CH) |
| Application Number: | 13/514,308 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 9,067,896
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Helsinn Hlthcare | TRUSELTIQ | infigratinib phosphate | CAPSULE;ORAL | 214622-001 | May 28, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Helsinn Hlthcare | TRUSELTIQ | infigratinib phosphate | CAPSULE;ORAL | 214622-002 | May 28, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,067,896
| PCT Information | |||
| PCT Filed | December 06, 2010 | PCT Application Number: | PCT/US2010/059108 |
| PCT Publication Date: | June 16, 2011 | PCT Publication Number: | WO2011/071821 |
International Family Members for US Patent 9,067,896
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 079257 | ⤷ Try a Trial | |||
| Argentina | 114946 | ⤷ Try a Trial | |||
| Australia | 2010328391 | ⤷ Try a Trial | |||
| Brazil | 112012013784 | ⤷ Try a Trial | |||
| Canada | 2781431 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
